ArticleOncology reports2017

Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma.

Jianhua Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.